Kedudukan dalam Saham
#16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Perubahan (1 hari)
-2.24%
Perubahan (1 tahun)
-22.64%
Perdagangan AP Biosciences Inc (6945)
Harga 6945 dengan permodalan pasaran b
Modal pasaran bagi AP Biosciences Inc(6945)
Modal Pasaran: $296.40M
Sehingga September 2026, AP Biosciences Inc mempunyai modal pasaran sebanyak $296.40M. Ini menjadikan AP Biosciences Inc syarikat ke-16392nd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran AP Biosciences Inc dari 2023 hingga 2026
6945 berbanding dengan 5 teratas yang paling popular stocks
| Harga 6945 |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.260T
|
+1,774,392.01%
|
|
|
|
|
$4.779T
|
+1,612,085.39%
|
|
|
|
|
$4.017T
|
+1,355,071.84%
|
|
|
|
|
$3.719T
|
+1,254,724.12%
|
|
|
|
|
$2.734T
|
+922,380.34%
|
